ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Interventional Mitral Valve Edge-to-Edge Repair in Patients Above 85 Years of Age.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitral valve transcatheter-edge-to-edge repair (M-TEER) is routinely performed in patients with severe mitral regurgitation (MR) at high operative risk, frequently including elderly patients. Patients ≥ 85 years, however, are frequently excluded in clinical studies.
objectivesWe evaluated differences of procedural characteristics and outcomes following M-TEER in patients < versus ≥ 85 years.
methodsWe retrospectively included consecutive patients with severe MR who underwent M-TEER with the PASCAL device between 2019 and 2024 at our center. Baseline and procedural characteristics, short- and mid-term outcomes were compared, stratifying the cohort into patients < versus ≥ 85 years.
resultsThree hundred seventy-five patients with moderate to severe or severe MR were eligible; 71 aged ≥ 85 (87.0 ± 1.7 years, 57.7% male) and 304 aged < 85 (75.5 ± 10.0 years, 58.6% male) years. Patients aged ≥ 85 years more frequently had severe MR (90.1% vs. 73.8%, p = 0.005) and higher STS-Score (6.4 [3.8; 9.1] vs. 3.5 [2.2; 6.5], p < 0.0001) at baseline. No leaflet injury, single leaflet detachment or any other device-related complication was observed, irrespective of age. Residual MR at 90 days was comparable among age groups (Trace: 34.8% vs. 23.8%; mild: 41.3% vs. 57.3%; moderate: 23.9% vs. 18.5%; moderate-severe: 0% vs. 0.4%, p = 0.56). Within 30 days, no death occurred in patients aged ≥ 85 years (one death in the < 85 years group). Median mid-term follow-up was 430 [164; 692] days. Overall mortality was not different for patients ≥ versus < 85 years (5.6% vs. 7.6%, p = 0.76).
conclusionM-TEER is safe in patients ≥ 85 years, with procedural outcomes and mid-term prognosis similar to younger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.